Almirall, SA (ALM) reported total revenues of 731.2 million euros in September, 8.1% more than in the same period in 2023, as reported on Monday.
The net sales of the Barcelona-based pharmaceutical company increased by 7.9% in the first nine months to 727.6 million and Ebitda was 142.2 million (+2.9% year-on-year), figures derived «from the dermatology business and particularly from the biologics portfolio in Europe.»
Almirall reiterated its financial forecasts for 2024, with high single-digit net sales growth and an Ebitda between 175 and 190 million euros.
The launch of Ebglyss in the main European markets generated 20.4 million in the first nine months, a quarterly sales increase of 34%, while Ilumetri generated 152.5 million in total sales, a 24.8% year-on-year increase.
«The geographic expansion of Ebglyss following the initial launch in Germany continues as planned with recent launches in Norway, the UK, Spain, Denmark, and the Czech Republic,» they explain.
«This growth, along with the success of our expanded dermatology portfolio, is a testament to our strong commercial capabilities and reinforces the foundation of our leadership in medical dermatology, in line with our company’s ambition,» explained Almirall’s President and CEO, Carlos Gallardo.
